CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks-A prospective randomized phase III study

被引：8
|
作者：
Sinn, Marianne
Liersch, Torsten
Gellert, Klaus
Messmann, Helmut
Bechstein, Wolf O.
Waldschmidt, Dirk
Jacobasch, Lutz
Wilhelm, Martin
Rau, Bettina M.
Gruetzmann, Robert
Weinmann, Arndt
Maschmeyer, Georg
Pelzer, Uwe
Stieler, Jens
Striefler, Jana Kaethe
Ghadimi, B. Michael
Bahra, Marcus
Oettle, Helmut
Doerken, Bernd
Riess, Hanno
机构：
[1] Charite, Med Oncol, D-13353 Berlin, Germany
[2] Univ Gottingen, Univ Med Ctr, Dept Gen Visceral & Pediat Surg, D-37073 Gottingen, Germany
[3] Sana Klinikum Lichtenberg, Dept Gen & Visceral Surg, Berlin, Germany
[4] Klinikum Augsburg, Dept Gastroenterol, Augsburg, Germany
[5] Univ Hosp Frankfurt, Dept Gen & Visceral Surg, Frankfurt, Germany
[6] Univ Cologne, Dept Gastroenterol & Hepatol, D-50931 Cologne, Germany
[7] Klinikum Nuernberg, Nurnberg, Germany
[8] Univ Med Rostock, Dept Gen Thorac Vasc & Transplantat Surg, Rostock, Germany
[9] Univ Klinikum Carl Gustav Carus, Dept Gen Thorac & Vasc Surg, Dresden, Germany
[10] Klinikum Johannes Gutenberg Univ, Dept Gastroenterol, Mainz, Germany
[11] Potsdam Klinikum, Potsdam, Germany
[12] Charite, Med Oncol, D-13353 Berlin, Germany
[13] Charite, Dept Gen Visceral & Transplantat Surg, Berlin, Germany
[14] Outpatient Dept Hematol Oncol, Friedrichshafen, Germany
[15] Charite, Campus Virchow Klinikum, Internist Onkol, D-13353 Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.4007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4007
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials
    Ottaiano, Alessandro
    Capozzi, Monica
    De Divitiis, Chiara
    De Stefano, Alfonso
    Botti, Gerardo
    Avallone, Antonio
    Tafuto, Salvatore
    ACTA ONCOLOGICA, 2017, 56 (03) : 377 - 383
  • [22] Randomized, cross-over phase III study of gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer - a multicenter trial of the "Arbeitsgemeinschaft Internistische Onkologie" (AIO)
    Boeck, S.
    Vehling-Kaiser, U.
    Waldschmidt, D.
    Kettner, E.
    Maerten, A.
    Winkelmann, C.
    Klein, S.
    Kojouharoff, G.
    Jung, A.
    Heinemann, V
    ONKOLOGIE, 2010, 33 : 25 - 25
  • [23] BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.
    Goncalves, A.
    Viret, F.
    Francois, E.
    Dahan, L.
    Perrier, H.
    Lamy, R.
    Re, D.
    Largillier, R.
    Gasmi, M.
    Tchiknavorian, X.
    Turrini, O.
    Moureau-Zabotto, L.
    Delpero, J.
    Viens, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727).
    Philip, Philip Agop
    Goldman, Bryan H.
    Ramanathan, Ramesh K.
    Lenz, Heinz-Josef
    Lowy, Andrew M.
    Whitehead, Robert P.
    Iqbal, Syma
    Gaur, Rakesh
    Benedetti, Jacqueline K.
    Blanke, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [25] A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201
    Loehrer, P. J., Sr.
    Powell, M. E.
    Cardenes, H. R.
    Wagner, L.
    Brell, J. M.
    Ramanathan, R. K.
    Crane, C. H.
    Alberts, S. R.
    Benson, A. B., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
    Scott, Aaron James
    O'Neil, Bert H.
    Ma, Wen Wee
    Cohen, Steven J.
    Aisner, Dara
    Menter, Alex R.
    Tejani, Mohamedtaki Abdulaziz
    Cho, Jonathan K.
    Rubin, Peter
    Coveler, Andrew L.
    Olowokure, Olugbenga Olanrele
    Baranda, Joaquina Celebre
    Cusnir, Mike
    Philip, Philip Agop
    Boles, Jeremiah
    Maguire, Robert T.
    Wilhelm, Francois
    Maniar, Manoj
    Gomes, Christina
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
    H Ueno
    T Kosuge
    Y Matsuyama
    J Yamamoto
    A Nakao
    S Egawa
    R Doi
    M Monden
    T Hatori
    M Tanaka
    M Shimada
    K Kanemitsu
    British Journal of Cancer, 2009, 101 : 908 - 915
  • [28] A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
    Ueno, H.
    Kosuge, T.
    Matsuyama, Y.
    Yamamoto, J.
    Nakao, A.
    Egawa, S.
    Doi, R.
    Monden, M.
    Hatori, T.
    Tanaka, M.
    Shimada, M.
    Kanemitsu, K.
    BRITISH JOURNAL OF CANCER, 2009, 101 (06) : 908 - 915
  • [29] Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial
    Tao Ma
    Xueli Bai
    Qichun Wei
    Yongjie Shui
    Mengyi Lao
    Wen Chen
    Bingfeng Huang
    Risheng Que
    Shunliang Gao
    Yun Zhang
    Wei Chen
    Ji Wang
    Tingbo Liang
    BMC Cancer, 22
  • [30] Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial
    Ma, Tao
    Bai, Xueli
    Wei, Qichun
    Shui, Yongjie
    Lao, Mengyi
    Chen, Wen
    Huang, Bingfeng
    Que, Risheng
    Gao, Shunliang
    Zhang, Yun
    Chen, Wei
    Wang, Ji
    Liang, Tingbo
    BMC CANCER, 2022, 22 (01)
12345